Dendreon leads drug stocks higher – MarketWatch
By Dr. Matthew Watson
 Artuji | Dendreon leads drug stocks higher MarketWatch The NYSE Arca Pharmaceutical Index (INDEX:DRG) edged up 0.4% at 299.09 and the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.7% to 1227.88. Dendreon's Clean Bill Of HealthForbes Major turnaround for Dendreon as US FDA approves Provenge for advanced ...The Pharma Letter Dendreon Shares Pop On Provenge ApprovalDaily Markets Orange County Business Journal -Puget Sound Business Journal -Comtex Smartrend all 976 news articles » |
Uncategorized
Comments Off on Dendreon leads drug stocks higher – MarketWatch |
May 2nd, 2010
This author published 5852 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research